FDA extends review on Valneva chikungunya vaccine by three months
The FDA has pushed its decision deadline on Valneva’s chikungunya vaccine to the end of November, the European vaccine company announced Monday morning.
Originally, the …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.